Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Activating EGFR Mutation”

132 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 132 results

Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Testing effectiveness (Phase 2)Ended earlyNCT02500927
What this trial is testing

ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Astellas Pharma Inc 31
Large-scale testing (Phase 3)Ended earlyNCT02326285
What this trial is testing

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

Who this might be right for
Non-squamous Non-small Cell Lung Cancer Stage IINon-squamous Non-small Cell Lung Cancer Stage IIIANon-squamous Non-small Cell Lung Cancer Stage IIIB+2 more
AIO-Studien-gGmbH 1
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)Study completedNCT05146219
What this trial is testing

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Who this might be right for
NSCLCEGFR Activating MutationBrain Metastases+1 more
TYK Medicines, Inc 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149
What this trial is testing

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Who this might be right for
AumolertinibAnlotinibTP53+2 more
Tianjin Medical University Cancer Institute and Hospital 47
Post-approval studies (Phase 4)Study completedNCT04511533
What this trial is testing

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Pfizer 101
Testing effectiveness (Phase 2)Study completedNCT02544997
What this trial is testing

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Who this might be right for
Metastatic Breast Cancer
Samsung Medical Center 5
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Large-scale testing (Phase 3)UnknownNCT02883543
What this trial is testing

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 330
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Post-approval studies (Phase 4)Study completedNCT01287754
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 24
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Large-scale testing (Phase 3)Study completedNCT02759614
What this trial is testing

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 311
Testing effectiveness (Phase 2)Study completedNCT03544814
What this trial is testing

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Shanghai Chest Hospital 99
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Testing effectiveness (Phase 2)Study completedNCT01221077
What this trial is testing

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Who this might be right for
NSCLCNon Small Cell Lung Cancer
Astellas Pharma Inc 88
Testing effectiveness (Phase 2)Ended earlyNCT02095782
What this trial is testing

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 10
Testing effectiveness (Phase 2)UnknownNCT03341494
What this trial is testing

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Who this might be right for
NSCLC Stage IVChemotherapy Effect
Fujian Cancer Hospital 128
Load More Results